Search

Your search keyword '"M. Scherlinger"' showing total 52 results

Search Constraints

Start Over You searched for: Author "M. Scherlinger" Remove constraint Author: "M. Scherlinger" Language english Remove constraint Language: english
52 results on '"M. Scherlinger"'

Search Results

1. National committee statement as a missed opportunity to acknowledge the relevance of a biopsychosocial approach in understanding long COVID.

2. French protocol for the diagnosis and management of systemic lupus erythematosus.

3. The PP2A regulatory subunit PPP2R2A controls NAD + biosynthesis to regulate T cell subset differentiation in systemic autoimmunity.

5. Mind-body practices in chronic inflammatory arthritis.

6. CaMK4 controls follicular helper T cell expansion and function during normal and autoimmune T-dependent B cell responses.

7. Platelets are a major player and represent a therapeutic opportunity in systemic lupus erythematosus.

8. New and future therapies: Changes in the therapeutic armamentarium for SLE.

10. The role of platelets in immune-mediated inflammatory diseases.

11. Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases.

13. Neurotransmitters arrive to control systemic autoimmunity.

14. Immunological and translational key challenges in systemic lupus erythematosus: A symposium update.

15. Chronic stimulation with SARS-CoV-2 spike protein does not trigger autoimmunity.

16. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review.

17. Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis.

18. Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity.

19. Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the Pandemic.

20. PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma.

21. Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin-2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus.

22. The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription.

23. Difficulties and Psychological Impact of the SARS-CoV-2 Pandemic in Patients with Systemic Lupus Erythematosus: A Nationwide Patient Association Study.

24. Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study.

26. Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection.

27. Reactive oxygen species: The Yin and Yang in (auto-)immunity.

28. Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.

29. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis.

30. Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments.

31. Role of stress in the development of rheumatoid arthritis: a case-control study.

32. Ascorbate maintains a low plasma oxygen level.

33. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014.

34. Characteristics and opinions of MD-PhD students and graduates from different European countries: a study from the European MD-PhD Association.

36. Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus.

37. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.

38. Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients.

39. Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study.

40. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis.

41. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).

44. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.

45. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.

46. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets.

48. Serum sickness-like disease after switching to biosimilar infliximab.

49. New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus.

50. Biotherapies in systemic lupus erythematosus: New targets.

Catalog

Books, media, physical & digital resources